Non-Alcoholic Steatohepatitis: Opportunities in a Growing Market
Sponsored by: GlobalData
- Nash Treatment
- Nash Market
Date: 22 February
Time: 3PM London/10AM New York
The Non-Alcoholic Steatohepatitis (NASH) market is expected to undergo significant change and growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan). In this webinar, GlobalData will analyze the current NASH treatment landscape and provide detailed insights into the market dynamics of this newly recognized disorder. This webinar will include the evaluation of the commercial and clinical profiles of drugs in development for NASH, and their sales projections within NASH over a 2019–2029 forecast period.
Currently, the majority of physicians recommend lifestyle changes as the principal standard of care, particularly in those at early stages of their disease where mortality rates are low. Over the forecast period, GlobalData expects that due the large population and current treatment use being infrequent, there remains a significant opportunity for companies to introduce regulatory approved branded therapies which are expected to become widely used in NASH patients.
Mohammad Uddin, a Consultant at GlobalData, and Director of Epidemiology, Kasey Fu, will present the changing NASH treatment landscape between 2019 and 2029, drawing insights from GlobalData’s recently published report, Non-Alcoholic Steatohepatitis (NASH) Opportunity Analysis and Forecasts to 2029. The webinar will include insights from Key Opinion Leaders (KOLs) covering the most important unmet needs for NASH, as well as the opportunities which are likely to remain by the end of the forecast period. Tina Healy, Senior Director of Immunology at GlobalData, will moderate a Q&A session following the presentation.
Mohammad first joined GlobalData in 2018 as a Healthcare Analyst, a role in which he was responsible for delivering research and analysis for a wide range of disease areas, including IPF, SSc, RSV and influenza. Mohammad has attended multiple immunology conferences, producing both syndicated and custom analyses for GlobalData’s clients. Before joining GlobalData, Mohammad worked as a Business Development Associate at Decision Resources Group. Mohammad holds an MSc in Drug Discovery and Pharmaceutical Management at University College London and a BSc in Biomedical Science at St. George’s, University of London.
Director of Epidemiology
Kasey Fu, MPH is the Director of Epidemiology at GlobalData in Boston, where her primary responsibilities include producing descriptive and analytical epidemiological reports for major drug indications, monitoring and maintaining the company’s state-of-the-art epidemiology database, liaising with other company units in developing new products, and completing global consulting projects. Prior to joining GlobalData, Kasey worked as a Wilbur G. Downs Global Health Fellow at the Instituto Nacional de Salud of Colombia analyzing dengue epidemic trends, risk factors, and the effects of climate change using multivariate regression and spatial modeling. She also worked as a staff writer for the Yale-Tulane Virtual Medical Operations Center producing public health and epidemiology reports for US military operations and international aid efforts during catastrophic disasters. Kasey holds a Master of Public Health in the Epidemiology of Microbial Diseases from the Yale School of Public Health. She is also fluent in Chinese and proficient in Spanish.
Senior Director of Immunology
Tina manages the Immunology market analysis and forecasts portfolio and the Immunology competitive intelligence (CI) portfolio. Tina has over nine years’ experience in pharmaceutical market intelligence, three years’ experience in drug discovery, and a proven track record of disease and competitive analysis. Prior to her current role, Tina was an Engagement Manager with consulting firm Lifescience Dynamics, covering CI deep-dive and monitoring projects, as well as MR & MA projects. Prior to joining Lifescience Dynamics, Tina was the Director for Immunology at GlobalData, where she spent four and a half years managing the production of syndicated reports and product forecasts in autoimmune diseases. Prior to GlobalData, Tina was an Analyst at Datamonitor, covering the Immunology-Inflammation portfolio, where she authored numerous in-depth analyses of products and companies and produced sales- and patient-based indication-specific forecasts. Tina has experience working within drug discovery with GSK and holds a Master’s degree in Medicinal Chemistry from University College London (UCL).
Key Learning Objectives
- Learn how GlobalData expects the NASH landscape to change between 2019 and 2029 across the seven major markets (US, France, Germany, Italy, Spain, the UK and Japan).
- Gain insight on the late-stage pipeline for NASH, including which products GlobalData expects to succeed, and why.
- Learn which unmet needs KOLs identified in the NASH treatment landscape, and whether or not they are likely to be met by the current pipeline .
- Identify which companies are set to be the major players in the NASH market during the forecast period.
- Managers/Senior Managers/Associate Directors/Directors of Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers